Allergen Tablet Production Capacity Has Expanded
A new manufacturing agreement aims to secure the long-term supply of allergy treatments for patients worldwide.
Updated on Sept. 30, 2026 in Allergies
Live Poll
Do you believe long-term pharmaceutical manufacturing partnerships increase drug availability for patients?
ALK has announced an expanded partnership with Catalent to significantly increase the production of its sublingual allergen immunotherapy tablets. This move is designed to ensure supply robustness for patients who rely on these daily treatments to manage their allergies.
Why it matters
Securing long-term manufacturing capacity helps prevent potential treatment interruptions for those managing chronic allergic conditions. This investment addresses the expected rise in future demand for specialized immunotherapy tablet portfolios.
The plan centers on a DKK 500 million investment over three years to boost production capacity. This aims to increase total output to 1.1 billion tablets annually by the early 2030s, supporting a long-standing manufacturing relationship that has spanned two decades.
The players
ALK
A Denmark-based pharmaceutical company specializing in allergy research and the development of immunotherapy treatments.
Catalent
A global contract development and manufacturing organization known for its proprietary Zydis oral dissolving tablet technology.
The details
The expansion leverages Catalent’s specialized Zydis tablet technology, which is designed to dissolve rapidly in the mouth. By scaling infrastructure at production sites in the UK and Canada, the agreement increases the capacity to manufacture sublingual immunotherapy, a treatment route that introduces allergens to the body to modulate the immune system's response over time.
Timeline
September 30, 2026: ALK announced the expanded manufacturing partnership.
Next three years: ALK will deploy the DKK 500 million capital investment.
Early 2030s: Increased production capacity of 1.1 billion tablets begins.
Health Landscape
The expansion of the SLIT tablet portfolio manufacturing line marks a departure from traditional injection-based allergy care by shifting toward stable, patient-administered oral treatments. This development secures the supply chain for these therapies, reinforcing the role of oral immunotherapy.
This development focuses on long-term supply stability and does not currently change your existing prescription or treatment plan. If you are using immunotherapy tablets, continue your prescribed regimen and consult your physician regarding any questions about treatment continuity or availability.
The takeaway
This manufacturing update aims to stabilize the supply of long-term allergy immunotherapy treatments. Patients should continue to discuss their specific treatment milestones and any concerns about ongoing care with their allergist or primary care physician.
Further reading
For more on how sublingual immunotherapy works to desensitize the immune system, visit our guide on Allergies.
Live Poll
Do you believe long-term pharmaceutical manufacturing partnerships increase drug availability for patients?
